【作者】 Liu Ji-ye (刘继业), Chen Ying-hua (陈英华)

【机构】 本站原创

【摘要】

Objective: To prove the feasibility and validity of Xing Nao Jing acupoint-injection (XNJ-AI) at Fengchi (GB 20) for pseudobulbar palsy caused by ischemic stroke (PBP-IS).

Methods: An assessor-blinded, two-parallel-group, randomized controlled trial was conducted, and the patients with PBP-IS were recruited and randomly divided into two groups. Patients in the control group received oral aspirin (100 mg per day for 2 weeks). In addition to oral aspirin; patients in the treatment group received XNJ-AI at Fengchi (GB 20), once a day, for two weeks. The primary outcome was assessed by the water-swallowing test (WST). Thromboxane B2 (TXB2) and 6-keto-prostaglandin F1a (6-keto-PGF1a) in plasma were measured before and after the treatment.

Results: In the treatment group, the percentage of swallowing function no less than grade 3 before and after the treatment was 32% and 88%, respectively; in the control group, it was 28% and 76% before and after the treatment, respectively; the difference after the treatment between the two groups was statistically significant (P＜0.05). There were statistical differences between pre- and post-treatment levels of plasma TXB2 and 6-keto-PGF1α in the two groups (both P＜0.05). After the treatment, there were significant differences in the levels of plasma TXB2 and 6-keto-PGF1α between the two groups (both P＜0.05).

Conclusion: XNJ-AI at Fengchi (GB 20) can improve the patients’ swallowing function and balance the levels of TXB2 and 6-keto-PGF1α in plasma.